Citadel Advisors’s InspireMD, Inc. Series B Warrants NSPRZ Stock Holding History

Citadel Advisors’s Portfolio NSPRZ Stock Details NSPRZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-40,919	Closed	-$2K	–	14802
2021 Q1	$2K	Sell	40,919 -23,550	-37%	-$1.12K	﹤0.01%	13103
2020 Q4	$1K	Sell	64,469 -1,100	-2%	-$14	﹤0.01%	10842
2020 Q3	$1K	Buy	+65,569	New	+$905	﹤0.01%	9982
2020 Q2	–	Sell	-16,223	Closed	–	–	10779
2020 Q1	$0	Buy	+16,223	New	+$128	﹤0.01%	10449
2019 Q2	–	Sell	-11,059	Closed	–	–	10131
2019 Q1	$0	Buy	+11,059	New	+$13	﹤0.01%	10113

Other funds holding NSPRZ

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's NSPRZ Position: Q2 2021 in Review

Citadel Advisors sold out of InspireMD, Inc. Series B Warrants (NSPRZ) in Q2 2021, closing a stake of 40,919 shares — an estimated $2K sold.

Citadel Advisors first reported a position in NSPRZ in Q1 2019 and held it in 5 quarters. The position peaked at $2K in Q1 2021. 2 funds tracked by Wall St. Rank hold NSPRZ as of Q2 2021.

Citadel Advisors reported no remaining InspireMD, Inc. Series B Warrants position as of Q2 2021 after selling out during the quarter.
Citadel Advisors sold 40,919 InspireMD, Inc. Series B Warrants shares in Q2 2021, an estimated $2K.
Citadel Advisors first reported a position in InspireMD, Inc. Series B Warrants in Q1 2019 and held it in 5 quarters.
Citadel Advisors's InspireMD, Inc. Series B Warrants position peaked at $2K in Q1 2021.
2 funds tracked by Wall St. Rank held InspireMD, Inc. Series B Warrants as of Q2 2021.

Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.